Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Legend Biotech Usa Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. The profile identifies 4 distinct examiners and 4 distinct art units. DONOGHUE, BRITTNEY ERIN is the busiest examiner, with 1 pending matter. The record shows prosecution activity distributed across four examination assignments involving the company’s biotechnology and pharmaceutical subject matter.
This structure calls for disciplined matter-level management. Counsel should track each action against its examiner and art unit, coordinate common claim and disclosure positions, and tailor substantive arguments to the individual record. A centralized review can identify consistent portfolio themes, but a response in one assignment should not be assumed to resolve the issues in another. The action assigned to DONOGHUE, BRITTNEY ERIN is one component of the pending workload.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DONOGHUE, BRITTNEY ERIN | 1 | 58.7% | +47.4% |
| GEORGE, DENNIS CHERIAN | 1 | 42.9% | +72.7% |
| BATES, KEENAN ALEXANDER | 1 | 44.9% | +79.8% |
| EDGINGTONGIORDANO, FRANCESCA | 1 | 71.8% | +29.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18175347 | BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA | DONOGHUE, BRITTNEY ERIN | 47d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17740665 | METHODS OF MINIMIZING NEUROTOXICITY ASSOCIATED WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY | BATES, KEENAN ALEXANDER | 10d overdue |
| 18175347 | BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA | DONOGHUE, BRITTNEY ERIN | 47d |
| 17784489 | SINGLE DOMAIN ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOF | GEORGE, DENNIS CHERIAN | — |
| 17251310 | ENGINEERED CELLS AND USES THEREOF | EDGINGTONGIORDANO, FRANCESCA | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| 1644 | 1 |
| 1631 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18175347 | BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA | DONOGHUE, BRITTNEY ERIN | 1675 | §103§112Other | Final Rejection | 47d | Pending | Feb 27, 2023 |
| 17784489 | SINGLE DOMAIN ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOF | GEORGE, DENNIS CHERIAN | 1644 | §102§103§112DP | Non-Final OA | — | Pending | Jun 10, 2022 |
| 17740665 | METHODS OF MINIMIZING NEUROTOXICITY ASSOCIATED WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY | BATES, KEENAN ALEXANDER | 1631 | §112 | Final Rejection | 10d overdue | Pending | May 10, 2022 |
| 17251310 | ENGINEERED CELLS AND USES THEREOF | EDGINGTONGIORDANO, FRANCESCA | 1643 | §103 | Non-Final OA | — | Pending | Dec 17, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLegend Biotech Usa Inc. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Brittney Erin Donoghue has the most, with 1 of Legend Biotech Usa Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
